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ABSTRACT
Background: Choline is obtained from the diet and from the bio-
synthesis of phosphatidylcholine. Phosphatidylcholine is catalyzed
by the enzyme phosphatidylethanolamine-N-methyltransferase (PEMT),
which is induced by estrogen. Because they have lower estrogen
concentrations, postmenopausal women are more susceptible to the
risk of organ dysfunction in response to a low-choline diet. A com-
mon genetic polymorphism (rs12325817) in the PEMT gene can
also increase this risk.
Objective: The objective was to determine whether the risk of low
choline–related organ dysfunction increases with the number of
alleles of rs12325817 in premenopausal women and whether post-
menopausal women (with or without rs12325817) treated with es-
trogen are more resistant to developing such symptoms.
Design: Premenopausal women (n = 27) consumed a choline-suffi-
cient diet followed by a very-low-choline diet until they developed
organ dysfunction (or for 42 d), which was followed by a high-
choline diet. Postmenopausal women (n = 22) were placed on the
same diets but were first randomly assigned to receive estrogen or
a placebo. The women were monitored for organ dysfunction and
plasma choline metabolites and were genotyped for rs12325817.
Results: A dose-response effect of rs12325817 on the risk of choline-
related organ dysfunction was observed in premenopausal women:
80%, 43%, and 13% of women with 2, 1, or 0 alleles, respectively,
developed organ dysfunction. Among postmenopausal women, 73%
who received placebo but only 18% who received estrogen developed
organ dysfunction during the low-choline diet.
Conclusions: Because of their lower estrogen concentrations, post-
menopausal women have a higher dietary requirement for choline
than do premenopausal women. Choline requirements for both
groups of women are further increased by rs12325817. This trial
was registered at clinicaltrials.gov as NCT00065546. Am J Clin
Nutr 2010;92:1113–9.
INTRODUCTION
Choline or its metabolites ensures the structural integrity and
signaling functions of cell membranes, is the major source of
methyl groups in the diet (one of choline’s metabolites, betaine,
participates in the methylation of homocysteine to form methi-
onine), and is important for cholinergic neurotransmission and
lipid transport from the liver (1). The recommended Adequate
Intake of choline by the Institute of Medicine of the National
Academy of Sciences is 550 mg/d for men and 425 mg/d for
women (2). Choline is found in a wide variety of foods that
contain membranes, such as eggs and organ meats (3, 4). The
only source of choline other than the diet is from the de novo
biosynthesis of phosphatidylcholine, which is catalyzed by
phosphatidylethanolamine-N-methyltransferase (PEMT) (1). The
PEMT gene has several estrogen response elements in its pro-
moter region, and the gene is induced by estrogen (5). Female
mice produce more phosphatidylcholine via the PEMT pathway
than do male mice (6) and estradiol-treated castrated rats have
more hepatic PEMT activity than do untreated controls (7). Es-
trogen likewise is a mediator of increased PEMT activity in hu-
mans (5). When deprived of dietary choline, almost 80% of men
and postmenopausal women developed liver or muscle damage,
whereas only 43% of premenopausal women developed such
signs of organ dysfunction (8). It makes sense, from an evolu-
tionary perspective, that young women can supply more of their
choline requirement from endogenous biosynthesis because
pregnancy and lactation are times when the demand for choline is
especially high, particularly to support the developing nervous
system (9, 10).
Susceptibility to choline-related organ dysfunction among
women is increased by a haplotype characterized by a common
single nucleotide polymorphism (SNP) in the PEMT gene
(rs12325817; almost 75% of the North Carolina population in
the United States has one variant allele) (11); having 1 or 2
variant alleles increased the likelihood of developing organ
dysfunction when choline was removed from the diet (odds ra-
tio: 21; P = 9 · 1026); a total of 64 women have now completed
the same clinical protocol).
In the current study, we tested the hypothesis that post-
menopausal women who are treated with estrogen will have
a lower risk of developing organ dysfunction while consuming
a low-choline diet than will postmenopausal women not treated
with estrogen. We hypothesized that women with at least one
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normal allele for PEMT will be estrogen responsive. We also
examined whether the PEMT rs12325817 SNP has a dose-




Healthy pre- and postmenopausal women (defined as having
had their last spontaneous menstrual bleeding .12 mo pre-
viously and as having a follicle stimulating hormone concen-
tration .30 IU/L) were recruited for a protocol approved by the
Institutional Review Board at the University of North Carolina at
Chapel Hill. Written informed consent was obtained from all
participants before initiating any study activities. Subject en-
rollment began on 27 June 2007. Of the initially recruited 58
subjects, 49 (27 premenopausal, 22 postmenopausal) participants
completed the study per protocol, whereas 9 (2 premenopausal, 7
postmenopausal) voluntarily dropped out or were discharged for
various reasons, including claustrophobia or an abnormal liver as
determined by magnetic resonance imaging (MRI) at study en-
try. The 27 premenopausal subjects who completed the study
ranged in age from 18 to 49 y and had a body mass index (BMI;
in kg/m2) between 18 and 30. The 22 postmenopausal subjects
who completed the study ranged in age from 50 to 73 y and had
a BMI between 20 and 32. The ethnic heritages of the 27 pre-
menopausal subjects were white (44%), African American
(30%), Asian (11%), Hispanic (11%), and Native American
(4%), whereas the ethnic distribution of the 22 postmenopausal
subjects (Table 1) was white (64%), African American (27%),
and Hispanic (9%), which reflected the local population char-
acteristics of the Raleigh-Durham-Chapel Hill area.
Inclusion was contingent on being a woman in a good state of
health as determined by physical examination and standard
clinical laboratory tests, having a normal mammogram in the past
12 mo (for postmenopausal subjects only), and having a BMI
between 18 and 34. Subjects were excluded if they were using
drugs or medications known to be damaging to liver or muscle at
typically prescribed doses or that had the potential to alter choline
metabolism (eg, methotrexate); had a history of hepatic, renal, or
other chronic systemic disease; bleeding or a blood-clotting
disorder; gastric bypass; breast, uterine, or other estrogen-
dependent cancer; anemia; positive serology for HIV; or hepatitis
B or C. Individuals who were current smokers, who consumed.2
alcoholic beverages/d or .14/wk, who were substance abusers
or drug addicted, who were eating unusual diets that would in-
terfere with the study, who had an allergy to soy, or who were
using choline-containing dietary supplements during the pre-
vious 30 d were likewise ineligible. We also excluded post-
menopausal women who were being treated with hormone
therapy or premenopausal women who were planning on be-
coming pregnant in the near future. Finally, individuals with
a pacemaker or other device that would make an MRI unsafe
(eg, cochlear implants, metal aneurysm clip) were not eligible.
Study design
On entry to the study the participants were admitted to the
University of North Carolina at Chapel Hill Clinical and
Translational Research Center, where they remained under the
constant supervision of study staff for the entire duration of the
study. Postmenopausal subjects were randomly assigned to re-
ceive estrogen (0.625 mg conjugated equine estrogen/d; Pre-
marin; Wyeth Pharmaceuticals, Philadelphia, PA) or a placebo
from day 1 until the end of the study.
The diets administered to the subjects, which were composed
of 0.8 g high biologic value protein/kg [current Recommended
Dietary Allowance (RDA)], with 30% kcal coming from fat and
the remaining kcal from carbohydrate, were prepared in-house to
TABLE 1





Age (y) 64 6 22 59 6 2
BMI (kg/m2) 25.9 6 1.3 27.8 6 0.4
Race [n (%)]
White 9 (82) 5 (45.5)
African American 1 (9) 5 (45.5)
Hispanic 1 (9) 1 (9)
Plasma estrogen (pg/mL)
Start of study ,20 ,20
End of study ,20 69 6 213
Change in liver fat (%)
End of depletion 32 6 10 8 6 73
End of study 2.8 6 0.8 25.3 6 4
1 Subjects were enrolled into the study and randomly assigned to receive either a placebo or estrogen-replacement
therapy (0.625 mg conjugated equine estrogen/d; Premarin; Wyeth Pharmaceuticals, Philadelphia, PA) from day 1 until the
last day of participation. Demographic information at study entry is presented for both groups. Estrogen was measured from
a blood sample collected on study entry and on the last day of study participation. Liver fat (measured at the end of the
depletion phase and at the end of the study) was measured as the change in ratio of liver to spleen fat determined by magnetic
resonance imaging as described in Subjects and Methods. Continuous and categorical variables were compared between the
estrogen and placebo groups by using a t test and Fisher’s exact test, respectively.
2 Mean 6 SEM (all such values).
3 Significantly different from the placebo group, P , 0.05.
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protocol specifications and are described in detail elsewhere (12).
Total food intake was adjusted to be isocaloric and to provide
adequate intakes of macro- and micronutrients. All diets met or
exceeded the Estimated Average Requirement for methionine plus
cysteine, and the RDA for vitamins B-12, B-6, and folate.
A multivitamin supplement (Kirkland Signature Daily Multi
Vitamins and Minerals; Costco, Seattle, WA) provided vitamins
and minerals at or above the RDA or Adequate Intake. Subjects
were also given a dietary supplement containing the RDA of
magnesium and 1.5 times the Adequate Intake of calcium (Cal-
cium Magnesium Complex; Vitamin Shoppe, North Bergen, NJ).
Initially, all subjects consumed a conventional diet of normal
foods delivering 550 mg choline/70 kg body weight daily [the
current Adequate Intake (2)], and 50 mg betaine/70 kg body
weight daily (baseline). After 10 d of this initial diet, the subjects
were switched to a low-choline diet containing ,50 mg choline/
70 kg body weight daily (with 6 mg betaine/70 kg body weight
daily), as confirmed by chemical analysis of a sample of du-
plicate food portions (3, 13). Periodic determinations of urinary
betaine concentrations (13) were used to confirm compliance
with the dietary restrictions (data not shown). Subjects remained
on the depletion diet until they developed organ dysfunction
associated with choline deficiency or for 42 d if they did not.
The subjects were deemed to have organ dysfunction associated
with choline deficiency if they had a .1.5-fold increase in as-
partate aminotransferase (AST) or alanine aminotransferase
(ALT), a .5-fold increase in creatine phosphokinase (CPK), or
an increase in liver fat content of .28% while consuming the
choline-depletion diet and if these increased measures resolved
when choline was returned to the diet.
After the subjects developed organ dysfunction associated
with choline deficiency, or if they did not by the end of the 42-d
period, they were transitioned to a choline-repletion diet (550–
850 mg/70 kg body weight daily) for up to10 d. The choline-
repletion diet was identical to the baseline diet, except for the
amount of choline. For the baseline and repletion phase diets, in
addition to the choline contributed by the foods, granulated
lecithin was used to add additional defined amounts of choline
into the diets. This was achieved by either baking it into a bread or
by using it as an ingredient in cookies. Subjects who manifested
signs of organ dysfunction that did not resolve after 10 d of the
repletion diet (n = 4) were sent home for 2 wk and instructed to
eat an ad libitum high-choline diet. They were then brought in
for repeat measures and a final study day.
Clinical assessment
A complete panel of laboratory tests was performed on each
subject at screening, on study entry (day 1), and at the end of each
dietary phase (baseline, depletion, and repletion). Blood was
drawn by venipuncture and sent to the McClendon Clinical
Laboratory at the University of North Carolina at Chapel Hill
Hospitals, which is accredited by both the Clinical Laboratory
Improvement Act (CLIA) and the College of American Patho-
logists (CAP). Laboratory markers measured included fasting
glucose, insulin, blood urea nitrogen, creatinine, alkaline phos-
phatase, AST, ALT, CPK, lactate dehydrogenase, total protein,
albumin, uric acid, total bilirubin, c-glutamyl transferase, amy-
lase, lipase, complete blood count with differential (white blood
cells, red blood cells, hemoglobin, hematocrit, platelet count,
mean cell volume, mean cell hemoglobin, mean cell hemoglobin
adjusted for cell volume, red blood cell distribution width,
neutrophils, lymphocytes, monocytes, eosinophils, and baso-
phils), prothrombin time, partial thromboplastin time, total
cholesterol, triglycerides, HDL, LDL, estrogen, folate, homo-
cysteine, C-reactive protein, and troponin-T. An abbreviated
toxicity panel, which included creatinine, AST, ALT, and CPK
was run every 3–4 d throughout the duration of the study to
monitor the depletion and repletion status of the subjects. Also,
pregnancy tests were performed on all premenopausal subjects
every 10–14 d throughout the duration of the study. Additional
samples of blood were collected to measure plasma choline and
related metabolite concentrations. Urinalysis was conducted at
screening and at the end of each dietary phase. The urinalysis
included measurements of betaine, specific gravity, pH, protein,
glucose, and myoglobin. The urinary betaine concentration was
used as a means of assessing noncompliance with the choline-
depletion diet (ie, cheating). These concentrations decreased
(compared with basal concentrations measured at the end of the
baseline diet) and remained low during the depletion phase of
the study. They rose when choline was returned to the diet and
would also be expected to rise if subjects were to eat high-
choline foods during the choline-depletion phase. Each subject
also received an electrocardiogram at screening and on the last
day of the depletion and repletion diets.
Choline and methyl-group metabolites
Choline, phosphatidylcholine, sphingomyelin, and betaine
were extracted from plasma by the method of Bligh and Dyer
(14). Aqueous and organic compounds were separated, analyzed,
and quantified directly by using liquid chromatography elec-
trospray ionization-isotope dilution mass spectrometry after the
addition of internal standards labeled with stable isotopes to
correct for recovery (13).
Fatty liver
Liver fat was measured by MRI at the beginning (day 1) and
end (day 10) of the baseline (550 mg choline/70 kg body weight
daily) diet, after 21 and 42 d of the low-choline diet, and at the
end of the repletion period. Liver fat content was estimated by
MRI with a Siemens TRIO 3T clinical MR system with
a modified Dixon “In and Out of Phase” procedure (15, 16). This
approach used the differences in transverse magnetization in-
tensity after an ultrabrief time interval (FLASH; TE = 2.2 and
4.5 ms, flip angle = 80, and TR = 140 ms). Processing of
successive FLASH MRI images with software from Siemens
Medical Solutions (Malvern, PA) was used to estimate fat
content. Quantification of organ fat content was based on
measurements across 5 images (liver slices) per subject and
standardized by relating the results to the fat content of similarly
measured images of spleen (it was assumed that spleen fat re-
mained constant during the study and could be used to normalize
values over time). As described previously, we used a 28% in-
crease in the ratio of liver fat to spleen fat as a predetermined
threshold value for indicating liver dysfunction secondary to
choline deficiency (8). The 28% increase over baseline that we
chose for depletion was an average grade of moderate steatosis
from several published studies (17). All liver fat measurements
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were conducted within 2 d of the stipulated end of the study
period (there was some variation based on availability of MRI).
Genotyping
Blood samples were collected by venipuncture, and peripheral
lymphocytes were isolated from blood by Ficoll-Hypaque gra-
dient by using evacuated cell preparation tubes containing so-
dium citrate (Becton Dickinson, Franklin Lakes, NJ) (18, 19).
Genomic DNA was then extracted by using a PureGene kit
(Gentra Systems, Minneapolis, MN) according to the manu-
facturer’s instructions. The PEMT rs12325817 SNP occurs in the
middle of an Alu repeat and consequently is not detected in the
GWAS chip set. Therefore, we do not know whether it is as-
sociated with published haplotypes. It is found on chromosome
17 in gb37.1 and is a G to C conversion. Forward primers specific
to the rs12325817 allele were designed so that the SNP would be
located at the 3# end of the priming sequence, which allows for
specific polymerase chain reaction products to be synthesized
only if the primer is 100% complementary to its template DNA
(11). Primers were designed by using GeneFisher (http://bibiserv.
techfak.uni-bielefeld.de/genefisher) and purchased from Qiagen
Operon (Huntsville, AL). The polymerase chain reactions were
optimized for each pair of primers, and the products were vi-
sualized on a 1.5% agarose gel to determine the genotype.
Statistical methods
In the premenopausal subjects, statistical analyses were per-
formed in 27 subjects. Depletion status and genotype for
rs12325817 SNP was obtained for each subject, and a Cochran-
Armitage Test of Trend was performed to examine whether
depletion was associated with an increased likelihood of having
a C allele.
In the postmenopausal subjects, the primary statistical anal-
yses were performed by using the data from the 22 subjects (11 in
the estrogen-treated group and 11 in the placebo group) who
completed the study per protocol. Nine additional subjects en-
rolled in the study but dropped out or were asked to leave for
various reasons. These subjects were not included in these
analyses. In evaluating subject responses to the experimental
choline deprivation and repletion, the primary outcome variable
was the occurrence of organ dysfunction during consumption of
a low-choline diet as defined in Subjects and Methods. De-
scriptive statistics—including means, SDs, frequencies, and
percentages—were computed. Comparisons of continuous and
categorical variables between the placebo and estrogen-treated
groups were performed by using t tests and Fisher’s exact tests,
respectively.
Repeated-measures regression models were fit for each of the
4 continuous responses (choline, phosphatidylcholine, sphingo-
myelin, and betaine). The continuous response was checked for
the normality assumption required in regression models, and the
assumption was met in all cases. The predictors were dummy
variables created by the 8 possible combinations of diet periods
[study entry (day 1), baseline (day 10), depletion, and repletion]
and treatments (estrogen and placebo). Levene’s Test of Ho-
mogeneity (20) was used to test the homogeneity of variance
assumption, and in the cases when the assumption was not met
(betaine and choline) weighted least squares regression was
used with the weights being the reciprocal of the variance of the
residuals from the corresponding unweighted model. The cor-
relation between observations on the same subject at the 4 dif-
ferent diet periods was modeled with a compound symmetric
variance-covariance matrix, which was found to fit the observed
data. Comparisons between any of the diet periods, treatments, or
combinations thereof were able to be constructed via contrast
statements from the resulting model.
RESULTS
All diets, including the low-choline (depletion) diet, were well
tolerated by subjects and caused no side effects other than those
associated with the removal of choline (hepatic and muscle
dysfunction). Moreover, estrogen treatment was well tolerated
and did not cause any adverse events in the postmenopausal
participants.
Dose-response effect of PEMT rs12325817 SNP in
premenopausal subjects
Premenopausal subjects were genotyped for the rs12325817
SNP in the PEMT gene and were fed a low-choline diet as de-
scribed above. A significant dose-response effect was seen be-
tween the number of alleles of the rs12325817 SNP and risk of
low choline–related organ dysfunction (P = 0.02). Eighty per-
cent of the women who were homozygous for the SNP man-
ifested signs of choline depletion (liver or muscle dysfunction),
relative to 43% of subjects carrying one copy of the variant
allele and 13% of subjects without the SNP (Table 2).
Effect of estrogen treatment on susceptibility to low
choline–related organ dysfunction in postmenopausal
subjects
We measured estrogen concentrations in all postmenopausal
subjects at the beginning and end of their study participation. At
the start of the study, circulating estrogen concentrations in both
groups were not detectable (,20 pg/mL; Table 1). At the end of
TABLE 2
Risk of organ dysfunction in response to a low-choline diet in
premenopausal subjects carrying the phosphatidylethanolamine-N-
methyltransferase (PEMT) rs12325817 single nucleotide polymorphism1
Number with PEMT genotype
GG GC CC
Depleted 1 6 4
Not depleted 7 8 1
1 Premenopausal subjects consumed a baseline diet containing 550 mg
choline/70 kg body weight for 10 d and were then advanced to a choline-
depletion diet (,50 mg choline/70 kg body weight daily) until they devel-
oped signs of organ dysfunction or for 42 d. Finally, subjects received
a choline-repletion diet (550–850 mg choline/70 kg body weight daily) for
10 d. The numbers of subjects who manifested signs of low choline–related
organ dysfunction are shown by genotype: homozygous wild-type (GG),
heterozygous (GC), and homozygous (CC) for the PEMT rs12325817 single
nucleotide polymorphism. G is the major allele, and C is the variant allele.
A significant (P = 0.02) dose-response effect was observed based on the
Cochran-Armitage test.
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the study, hormone-treated subjects had, on average, signifi-
cantly higher circulating estrogen concentrations (69 pg/mL)
than did untreated subjects, which confirmed compliance with
the estrogen-replacement therapy, whereas none of the placebo
subjects had detectable concentrations. Note that the mean
concentration observed in the estrogen-treated group was beyond
the University of North Carolina at Chapel Hill McClendon
Clinical Laboratory normal range for postmenopausal women
(5–38 pg/mL).
Postmenopausal women receiving placebo were 4 times more
likely to develop liver dysfunction when fed the low-choline diet
than were those receiving estrogen (Table 3; P = 0.03). In the
placebo group, 7 of 8 women developed fatty liver as measured
by MRI when deprived of choline, and 1 subject was deemed
choline-depleted based on an elevation in AST concentration
(1.6 times the upper limit of normal) at the end of the baseline
phase. (Apparently, 550 mg choline/70 kg body weight daily
was not sufficient to meet this woman’s choline requirement.)
Per protocol, this subject skipped the depletion phase and was
directly advanced to the repletion phase. In the estrogen-treated
group, 2 women manifested organ dysfunction as fatty liver in
response to a low-choline diet. The difference in response to the
low-choline diet between the 2 groups is also reflected in the
mean percentage change in ratio of liver fat to spleen fat ob-
served at the end of the depletion phase (Table 1). In addition,
both groups, on average, had baseline levels of liver fat at the
end of the study that indicated that the choline in the repletion
diet was effective at resolving the observed liver dysfunction.
Influence of PEMT rs12325817 SNP on susceptibility
to choline-related organ dysfunction
We previously showed that postmenopausal women with the
haplotype characterized by the PEMT rs12325817 SNP have a far
greater likelihood of developing organ dysfunction when fed
a low-choline diet (11). Consistent with earlier findings, post-
menopausal women in the placebo group who carried 1 (GC ) or 2
(CC ) copies of the PEMT SNP were significantly more likely to
develop organ dysfunction when fed a low-choline diet than
were those with no copies of the SNP (GG; P = 0.02). In the
placebo group, one subject who was homozygous for this
SNP and 6 subjects who were heterozygous for the SNP de-
veloped organ dysfunction. Of the 4 subjects in the placebo
group without this SNP, 1 was choline-depleted and 3 were not
(Table 3).
Estrogen treatment mitigated this effect of the PEMT SNP.
Whereas 100% of women with one or more allele for the SNP
developed organ dysfunction in the placebo group, only 40%with
one or more allele for the SNP developed organ dysfunction in
the estrogen-treated group (P , 0.05). In the estrogen-treated
group, 5 subjects were heterozygous for the SNP (none were
homozygous). Of these subjects, 2 manifested signs of organ
dysfunction secondary to choline deficiency, whereas 3 did not.
In this group, there were also 6 subjects without the SNP; none
developed organ dysfunction after 42 d of the choline-depletion
diet (Table 3).
Choline and related metabolite concentrations in
placebo- and estrogen-treated subjects
We measured plasma concentrations of choline, phosphati-
dylcholine, sphingomyelin, and betaine in all postmenopausal
subjects at the end of each dietary phase (Table 4). None of the
metabolites were significantly different between the placebo and
estrogen groups at study entry (day 1). At the end of the baseline
phase (day 10), the betaine concentration was significantly
higher in the placebo group than in the estrogen group (P =
0.03). No statistically significant difference in the other 3 me-
tabolites was observed at the end of the baseline phase between
the placebo and estrogen groups. At the end of depletion, the
betaine concentration was again significantly higher in the pla-
cebo group than in the estrogen group (P = 0.009). No statisti-
cally significant differences in the other 3 metabolites were
observed at depletion between the placebo and estrogen groups.
The betaine concentration was likewise significantly higher in
the placebo group than in the estrogen-treated group at the end
of the repletion diet period (P = 0.003). No other significant
differences in the other metabolites were observed between the
treatment groups at any of the diet periods.
When looking at changes over time within groups, all
metabolites in the estrogen group changed significantly from
study entry (day 1) to day 10, and all metabolites in the placebo
group (with the exception of phosphatidylcholine) changed over
the same time period. Choline and betaine concentrations de-
creased significantly from baseline (day 10) to depletion (all
P values = 0.0001) in both the estrogen and placebo groups. This
TABLE 3
Frequency of organ dysfunction associated with choline deficiency in the placebo and estrogen-treated groups by phosphatidylethanolamine-N-
methyltransferase (PEMT) genotype1
Placebo group (n = 11) Estrogen-treated group (n = 11)
All GG GC CC All GG GC CC
Depleted (n) 8 1 6 1 2 0 2 0
Did not deplete (n) 3 3 0 0 9 6 3 0
Frequency of depletion (%) 73 25 100 100 182 0 40 —
1 Postmenopausal subjects were randomly assigned to receive a placebo or estrogen (0.625 mg conjugated equine estrogen/d; Premarin; Wyeth
Pharmaceuticals, Philadelphia, PA) from day 1 until the end of their study participation. They consumed a baseline diet containing 550 mg choline/70 kg
body weight for 10 d and then advanced to a choline-depletion diet (,50 mg choline/70 kg body weight daily) until they developed signs of organ dysfunction
or for 42 d. Finally, subjects received a choline-repletion diet (550–850 mg choline/70 kg body weight daily) for 10 d. The numbers of subjects who
manifested signs of low choline–related organ dysfunction are shown by genotype. Depletion outcomes are presented for subjects sorted by genotype (C =
variant allele): homozygous wild-type (GG), heterozygous (GC), and homozygous (CC) for the PEMT rs12325817 single nucleotide polymorphism.
2 Significantly different from the placebo group (all subjects combined), P , 0.05.
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also occurred independently of whether subjects developed or-
gan dysfunction (data not shown). None of the other metabolites
changed significantly from the end of baseline to depletion
within each group. Conversely, mean choline and betaine con-
centrations increased significantly from depletion to repletion
(all P values = 0.0001) in both groups, whereas the other me-
tabolites remained unchanged. Finally, a significant increase in
sphingomyelin (P = 0.02) and betaine (P = 0.04) concentrations
from baseline (day 10) to repletion was observed in the placebo
group. None of the other combinations of metabolites and time
points showed a statistically significant change from baseline to
repletion within each group.
DISCUSSION
To our knowledge, this was the first study to show that estrogen
treatment in postmenopausal women can decrease the dietary
requirement for the nutrient choline; ’4 times more women in
the placebo group than in the estrogen group developed liver
dysfunction when fed a low-choline diet.
In this study, choline deficiency was associated with fatty liver.
Nonalcoholic fatty liver occurs in ’25% of the population and
can be associated with progression to more severe liver disease
(21). Progression to fibrosis is much more common in men and
women older than 60 y of age, which suggests that estrogen
modulates liver fibrosis (22). It is interesting that individuals
with fatty liver have a higher prevalence of an exonic SNP in
PEMT (23)—the gene that catalyzes phosphatidylcholine syn-
thesis in the liver. In this study, postmenopausal women in the
placebo group who had a haplotype characterized by the
rs12325817 SNP in PEMT developed liver dysfunction when fed
a low-choline diet. Estrogen treatment reduced the risk of de-
veloping fatty liver in postmenopausal women with this SNP.
Although the experimental cohort was of a relatively small size,
we had sufficient statistical power to detect clinically important
differences.
Herein we showed that the PEMT rs12325817 SNP has a dose-
response effect on risk of choline-related organ dysfunction in
premenopausal women. We also confirmed previous results
showing that women (both pre- and postmenopausal) carrying 1
or 2 copies of the SNP have a significantly greater risk of de-
veloping liver or muscle dysfunction when fed a low-choline diet.
We had hoped to recruit more postmenopausal women who were
homozygous for this allele. However, despite all of our recruiting
efforts, we were only able to identify one postmenopausal subject
homozygous for this allele (CC) who was eligible to participate.
We do not know why this was the case and suspect that there
may be an underlying reason to explain why the homozygous
genotype occurs at a greater frequency in premenopausal women
(and men) who are eligible for our study than in postmenopausal
women. We hypothesize that one or more of the rigorous eli-
gibility criteria for the study may co-present with the homozy-
gous genotype in women after menopause and thus exclude such
individuals. This topic will be the subject of future studies.
No increases in plasma choline or its related metabolite
concentrations due to estrogen treatment were observed. The
concentrations of these metabolites in plasma are homeostatically
regulated and are not good indicators of intracellular choline
concentrations in liver (24). The estrogen-treated group had lower
betaine concentrations in plasma; perhaps choline dehydrogenase
is inhibited by estrogen. This may be yet another mechanism (in
addition to the induction of PEMT) that would result in sparing
choline pools in women. It is also possible that the betaine
concentration was lower in the estrogen-treated group because of
increased use of betaine as a methyl donor (PEMT is a major user
of S-adenosylmethionine). However animal studies conducted in
our laboratory have not been able to confirm this (unpublished
findings).
TABLE 4
Choline and metabolite concentrations in the placebo- and estrogen-treated postmenopausal women1
Time Choline PtdCho SM Betaine
nmol/mL nmol/mL nmol/mL nmol/mL
Placebo group
Study entry 7.7 6 0.52 1939 6 117 474 6 422 48 6 52
Baseline (day 10) 11.0 6 0.3 2000 6 118 392 6 28 88 6 11
Depletion 5.4 6 0.42 1916 6 140 406 6 30 41 6 92
Repletion 11.6 6 1.13 2067 6 126 438 6 382 123 6 192,3
Estrogen-treated group
Study entry 8.7 6 0.62 2073 6 982 427 6 492 43 6 42
Baseline (day 10) 11.9 6 0.8 2254 6 115 379 6 37 61 6 84
Depletion 5.6 6 0.42 2168 6 151 397 6 43 16 6 22,4
Repletion 13.4 6 1.73 2283 6 119 402 6 39 49 6 53,4
1 All values are means 6 SEs. Subjects were randomly assigned to receive either a placebo or estrogen-replacement
therapy and consumed a baseline diet containing 550 mg choline/70 kg body weight daily for 10 d. If subjects did not
manifest organ dysfunction during this diet, they were advanced to a choline-depletion diet (,50 mg choline/70 kg body
weight daily) until they developed signs of organ dysfunction or for 42 d. Subjects then received a choline-repletion diet
(550–850 mg choline/70 kg body weight daily) for 10 d. Blood was drawn from subjects at the end of each dietary phase.
Plasma choline, phosphatidylcholine (PtdCho), sphingomyelin (SM), and betaine concentrations were measured by using
liquid chromatography–mass spectrometry. Entries are for each group at the end of the indicated study phase.
2 Significantly different from baseline value within the same group, P , 0.05 (repeated-measures regression models).
3 Significantly different from depletion value within the same group, P , 0.05 (repeated-measures regression models).
4 Significantly different from corresponding value in the placebo group, P , 0.05 (repeated-measures regression
models).
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Because of increased risks of cancer and stroke associated with
hormone replacement therapy, current recommendations for
hormone replacement therapy in postmenopausal women suggest
that treatment be limited to short periods to reduce menopausal
symptoms (25). At the same time, dietary recommendations have
discouraged women from consuming high-choline foods such as
eggs and fatty meats, and the 2005 National Health and Nutrition
Examination Survey indicates that only 2% of postmenopausal
women consume the recommended intake of this nutrient (26,
27). Thus, postmenopausal women, especially those with SNPs in
genes that increase the dietary requirements for choline (11, 28),
may be at increased risk of low choline–related liver or muscle
dysfunction when their estrogen concentrations decline.
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